About Enhancer
| Enhancer ID: | E_00158 |
| Species: | Homo sapiens |
| Position : | chr3:181624870-181626200   |
| Year: | 2021 |
| Title: | A predominant enhancer co-amplified with the SOX2 oncogene is necessary and sufficient for its expression in squamous cancer |
| Genome Build: | hg19 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | breast carcinoma |
| PMID: | 34880227 |
| MONDO: | MONDO:0006120 |
| Tissue: | Breast |
| Tissue Ontology ID: | UBERON:0000310 |
| Cell Source: | MDA-MB-231 |
| CVCL ID: | CVCL_0062 |
| Cell Type: | breast carcinoma cell |
| Cell Ontology ID: | CL:0000066 |
| Experiment Type: | Enhancer activity assay, Functional perturbation assay |
| High Throughput Method: | ATAC-seq, ChIP-seq, RNA-seq, Hi-C |
| Low Throughput Method: | CRISPRi, Luciferase Reporter Assay, RT-RT-qPCR, ChIP-RT-qPCR |
About Target Gene
| Target gene : | SOX2 |
About TF
| TF name : | SOX2 |
About Regulatory State
| Regulatory State : | Active |
Upstream Pathway Annotation of TF
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| SOX2 | Deactivation of the beta-catenin transactivating complex | reactome | 42 |
| SOX2 | POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | reactome | 13 |
| SOX2 | POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | reactome | 10 |
| SOX2 | Transcriptional regulation of pluripotent stem cells | reactome | 28 |
| SOX2 | Hs_Endoderm_Differentiation_WP2853_88152 | wikipathways | 62 |
| SOX2 | Hs_Dopaminergic_Neurogenesis_WP2855_87239 | wikipathways | 19 |
| SOX2 | Hs_Wnt_Signaling_Pathway_and_Pluripotency_WP399_90291 | wikipathways | 12 |
| SOX2 | Hs_Mesodermal_Commitment_Pathway_WP2857_87780 | wikipathways | 47 |
| SOX2 | Hs_Ectoderm_Differentiation_WP2858_89329 | wikipathways | 56 |
Enhancer Associated Network
Overlapping Enhancers (hg19)
No overlapping enhancers found in hg19 at this locus.
Expression of Target Genes for the Enhancer